Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06034275 · ClinicalTrials.gov registry record · Phase 1
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
A Phase 1 study of Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia, sponsored by Vincerx Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT06034275 is a Phase 1 study of Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Vincerx Pharma. The registered enrollment target is 36 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06034275, a Phase 1 study of Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Vincerx Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Conditions Studied
Interventions
- DRUG VIP943 (QW)
- DRUG VIP943 (BIW)
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
Ohio
- University of Cincinnati - Cincinnati
Tennessee
- TriStar Bone Marrow Transplant - Nashville
Texas
- MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06034275
The ClinicalTrials.gov registry entry for NCT06034275 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (69% lower). The listed sponsor is Vincerx Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which VIP943 (QW) is the first listed.
NCT06034275 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06034275 about?
NCT06034275 is a clinical study titled "Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies". Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
What is the current status of trial NCT06034275?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-09-13. Estimated completion is 2025-12-31.
What conditions does trial NCT06034275 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High Risk Myelodysplastic Syndrome.
What interventions are being tested in trial NCT06034275?
The interventions under investigation include: VIP943 (QW) (DRUG), VIP943 (BIW) (DRUG).
Who is sponsoring clinical trial NCT06034275?
This trial is sponsored by Vincerx Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06034275 being conducted?
This trial has 5 study locations across Alabama, Ohio, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.